Drug Detail

Information about PX-478

Generic Name
IND
 PX-478
Brand Name (US)
Manufacturer
 Oncothyreon
Drug Type
 HIF-1a inhibitor
Delivery
 Oral
Approval Status
 Phase 1
Indications
Overall Strategy
 Oncogenic Signal Path Based
Strategy
 Block related tumor signal paths Block tumor blood vessel growth
Drug Category
 HIF-1α inhibitor

This drug is an oral HIF-1α Inhibitor. This type of inhibitor may have activity against certain pediatric type GISTs with defects in the SDH gene(s) (succinate dehydrogenase).
These types include Carney Stratakis syndrome and possible Carney's Triad.

Links

 

 Carney-Stratakis syndrome explained (LRG website)
   

 

 Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1{alpha}
   

 

 PX-478 Overview and Description
   

 

 PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells.
   

Trials of this drug

  

 Phase I Trial of PX-478
   

Trial results
  PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells.
   
  ASCO 2010 - Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.
   

Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed